Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis

Abstract Objectives Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS). Method Pooled data from Phase 2 (NCT01786668; 04/2013–03/2015)/Phase 3 (NCT03502616; 06/2018–08/2020) RCTs in AS patients were analyzed (3...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Atul Deodhar, Servet Akar, Jeffrey R. Curtis, Bassel El-Zorkany, Marina Magrey, Cunshan Wang, Joseph Wu, Solomon B. Makgoeng, Ivana Vranic, Sujatha Menon, Dona L. Fleishaker, Annette M. Diehl, Lara Fallon, Arne Yndestad, Robert B. M. Landewé
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2024-12-01
Ráidu:	Advances in Rheumatology
Fáttát:	Janus kinase inhibitors/adverse effects Spondylitis Ankylosing Tofacitinib
Liŋkkat:	https://doi.org/10.1186/s42358-024-00402-x
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!